University of Manchester, Manchester, UK.
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):6-20. doi: 10.1111/jth.15189.
Against a background of a rapidly evolving treatment landscape, a contemporary, evidence-based consolidated understanding of mortality in people with congenital hemophilia A (PwcHA) is lacking. This systematic literature review examines the available data on mortality and causes of death in PwcHA to enable a better understanding of fatalities in PwcHA and evaluate the impact of new treatment paradigms on mortality. A systematic literature review of observational studies was conducted by searching Medline, Embase, and clinical trials registries for articles published from January 2010 to March 2020, using the search terms: hemophilia A (HA), mortality, cause of death. Interventional studies, studies not reporting fatalities, and those reporting only on hemophilia B, acquired HA, or mixed other coagulopathies were excluded. Overall, 7818 unique records were identified and 17 were analyzed. Of these, six reported mortality rates and five reported mortality ratios. Mortality generally decreased over time, despite a spike associated with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection in the 1980s and 1990s. Mortality was strongly correlated with age and hemophilia severity. People with hemophilia had a raised mortality risk compared with the general population, particularly in severe hemophilia, and when infected with HIV or HCV. Causes of death varied across populations, countries, and time in 15 identified studies; however, incomplete and heterogeneous reporting limits evidence. Hemorrhage, HIV, HCV, and hepatic disease were the leading causes of death. A unified approach to reporting mortality and cause of death is needed to understand mortality in PwcHA as treatments continue to advance.
在治疗领域迅速发展的背景下,目前缺乏对先天性血友病 A 患者(PwcHA)死亡率的现代、基于证据的综合认识。本系统文献回顾检查了 PwcHA 死亡率和死亡原因的现有数据,以便更好地了解 PwcHA 的死亡情况,并评估新治疗模式对死亡率的影响。通过搜索 Medline、Embase 和临床试验登记处,使用“hemophilia A (HA)、mortality、cause of death”等搜索词,对 2010 年 1 月至 2020 年 3 月期间发表的观察性研究进行了系统文献回顾,排除了干预性研究、未报告死亡率的研究以及仅报告血友病 B、获得性血友病或混合其他凝血障碍的研究。总的来说,共确定了 7818 个独特的记录,分析了其中的 17 个。其中,6 个报告了死亡率,5 个报告了死亡率比。尽管在 20 世纪 80 年代和 90 年代与人类免疫缺陷病毒(HIV)/丙型肝炎病毒(HCV)感染相关的死亡率有所上升,但总体上死亡率随着时间的推移而下降。死亡率与年龄和血友病严重程度密切相关。与普通人群相比,血友病患者的死亡率风险更高,尤其是在严重血友病和感染 HIV 或 HCV 的情况下。在 15 项已确定的研究中,不同人群、国家和时间的死亡原因各不相同;然而,不完整和异质的报告限制了证据。出血、HIV、HCV 和肝脏疾病是主要的死亡原因。需要采用统一的方法报告死亡率和死亡原因,以了解随着治疗不断进步,PwcHA 的死亡率。